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Drug resistance is a recurrent problem in the ﬁght against malaria. Genetic and epidemiological sur-
veillance of antimalarial resistant parasite alleles is crucial to guide drug therapies and clinical man-
agement. New antimalarial compounds are currently at various stages of clinical trials and regulatory
evaluation. Using ~2000 Plasmodium falciparum genome sequences, we investigated the genetic diversity
of eleven gene-targets of promising antimalarial compounds and assessed their potential efﬁciency
across malaria endemic regions. We determined if the loci are under selection prior to the introduction of
new drugs and established a baseline of genetic variance, including potential resistant alleles, for future
surveillance programmes.
© 2017 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The continuous emergence and spread of resistance to ﬁrst line
antimalarial treatments, including artemisinin and its derivatives,
threatens global efforts to reduce the burden of malaria. The
development of a fully effective vaccine has been hampered by the
complex life cycle of the malaria parasite and the high genetic di-
versity of key parasite antigens. Thus, antimalarial drugs, particu-
larly those targeting basic cellular machinery common to all stages
of the parasite life cycle, are the most promising approaches to
control malaria.
The pipeline of antimalarial drugs has greatly expanded over the
past decade, particularly because of the strong public-private
partnerships and signiﬁcant investment in innovative technolo-
gies (Flannery et al., 2013; Wells et al., 2015). A set of next gener-
ation antimalarial compounds, for which the molecular targets are
known or being investigated, are currently at various phases of
preclinical and clinical assessment (Wells et al., 2015).
Knowledge of parasite molecular drug targets can be exploited
to monitor the potential emergence and spread of resistant alleles,
particularly from the introduction of a drug, and rapidly informampino).
Ltd on behalf of Australian Society flocal policies to tailor interventions. Without knowledge of anti-
malarial gene targets, the identiﬁcation and surveillance of resis-
tant alleles needs to be based on accurate clinical drug efﬁcacy trials
and genome-wide population genetic studies of ﬁeld collected
samples (Anderson et al., 2011). This approach can be both costly
and labour intensive. Alternatively, a powerful strategy to identify
mutations linked to resistance, prior to the licensing of a drug, is the
use of laboratory-adapted strains to induce selection in vitro with
sub-lethal and increasing concentrations of drugs. This strategy has
led to the identiﬁcation of polymorphisms in the Plasmodium (P)
falciparum kelch13 gene underlying resistance to artemisinin (Ariey
et al., 2014). This gene was conﬁrmed subsequently in association
studies in ﬁeld collected samples (Miotto et al., 2015) and using a
reverse genetics approach (Ghorbal et al., 2014).
Here we consider eleven gene-targets of key investigated
compounds that due to their efﬁciency might become the next
antimalarial drugs, and for which mutations conferring resistance
have been identiﬁed in in vitro studies (Baraga~na et al., 2015; Dong
et al., 2011; Flannery et al., 2015; Herman et al., 2015; Kato et al.,
2016; LaMonte et al., 2016; Lim et al., 2016; McNamara et al.,
2013; Ross et al., 2014). These 11 genes were also selected
because they are gene-targets for a range of new antimalarial
compounds already under evaluation in clinical trials. We present a
survey of the natural genetic variation (SNPs, insertions andor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
A.R. Gomes et al. / International Journal for Parasitology: Drugs and Drug Resistance 7 (2017) 174e180 175deletions (indels), copy number variants (CNVs)) and diversity in
these gene-targets using a publicly available global collection of
~2000 P. falciparum “ﬁeld” parasite genomes from 18 countries. We
use the variation to establish whether these regions are already
under selective pressure, and report a baseline reference to assist
future surveillance programmes with observing emergence of
resistance mutations.
2. Materials and methods
Eleven gene-targets were analysed: PF3D7_1113300 (Pfugt),
PF3D7_1036800 (Pfact), PF3D7_0109800 (PfcPheRs), PF3D7_0603300
(Pfdhodh), PF3D7_0509800 (Pfpi4k), PF3D7_0321900 (Pfcarl),
PF3D7_1211900 (Pfatp4), PF3D7_1451100 (PfeEF2), PF3D7_1320600
(Pfrab11A), PF3D7_1213800 (Pfprs) and Mal_Mito_3 (PfCYTB) (see
Table 1). Genome variation data was analysed for isolates from East
Africa (Kenya, Tanzania, n ¼ 35), West Africa (Burkina Faso, The
Gambia, Ghana, Guinea, Mali, Nigeria, n ¼ 521), Central Africa
(Democratic Republic of Congo (DRC), n ¼ 56), South America
(Colombia, Peru, n ¼ 24), South Asia (Bangladesh, n ¼ 53) and
Southeast Asia (Cambodia, Laos, Myanmar, Papua New Guinea,
Thailand, Vietnam, n ¼ 1187).
Sequencing data was generated by the Pf3k project (www.
malariagen.net/pf3k), is open access and is described in (Miotto
et al., 2015). Whole genome analysis of these data has also been
recently described (Ravenhall et al., 2016) and we used a set of
characterised high quality SNPs and indels identiﬁed in the 11
candidate target genes. In addition, larger structural variants (e.g.
CNVs) in these regions were identiﬁed using Delly software (Rausch
et al., 2012). Using the SNP variants, population genetic analyses
were performed to establish if targeted coding regions are under
selection. In particular, the Tajima's Dmethod was applied to detect
regions under balancing selection (R package Pegas); extended
haplotype homozygosity approaches (jiHSj, XP-EHH) were applied
to identify long-range positive directional selection, and FST sta-
tistics were used to assess population differentiation (seeTable 1
Drug targets and genetic polymorphisms.
Gene-target ID Gene Active Compounds
PfcPheRs (PF3D7_0109800) Phenylalanine-tRNA
ligase alpha subunit
Bicyclic azetidine
Pfcarl (PF3D7_0321900) Cyclic amine resistance
locus protein
Imidazolopiperazines,
benzimidazolyl piperidines
Pfpi4k (PF3D7_0509800) Phosphatidylinositol-4
kinase
Imidazopyrazines,
aminopyridine class,
quinoxaline,
2-aminopyradines
Pfdhodh (PF3D7_0603300) Ddihydroorotate
dehydrogenase
triazolopyrimidine-based
inhibitor, N-alkyl-5-thiophene-
2-carboxamides
Pfact (PF3D7_1036800) Acetyl-CoA
transporter
Imidazolopiperazines
Pfugt (PF3D7_1113300) UDP-galactose
transporter
Imidazolopiperazines
Pfatp4 (PF3D7_1211900) P-type cation
transporting ATPase
Spiroindolones, sulfonamide,
carboxamide,
pyrazoles,dihydroisoquinolones
Pfprs (PF3D7_1213800) Proline-tRNA
synthetase
Febrifugine and
derivates
Pfrab11A (PF3D7_1320600) Ras-related
protein Rab-11A
Aminopyridine class
PfeEF2 (PF3D7_1451100) Elongation factor 2 Quinoline-4-carboxamide
(DDD107498)
PfCYTB (mal_mito_3) Cytocrome b Atovaquone, tetracyclic
benzothiazepine,
benzylsulfonamide, decoquinate(Ravenhall et al., 2016) for a detailed description of these methods).
3. Results
Across the eleven gene-targets, a total of 778 SNPs were iden-
tiﬁed, with half (n ¼ 424, 54.5%) leading to non-synonymous
changes (Table 1, Supplementary Table 1). The overall genetic di-
versity was low, with the majority of SNPs (75.1%) having minor
allele frequencies of less than 5%. The SNP density (number of SNPs
per kbp) across genes was similar (~1 SNP per 33bp), except for
those coding for the ras-related protein (Rab11A, 1 SNP per
258.6bp), elongation factor 2 (eEF2, 1 SNP per 73.4bp) and the
acetyl-CoA transporter (ACT, 1 SNP per 64.2bp), all with lower
density, suggesting greater gene conservation. The pfact gene was
recently identiﬁed to be the target, together with the UDP-
galactose transporter gene-target (Pfugt), of a variety of imidazo-
lopiperazine compounds. One of these compounds (KAF156) has
potent activity against gametocytes and parasite liver stages, and is
currently in Phase II clinical trial (Lim et al., 2016). Rab11A is a
molecular target for aminopyridine class compounds (McNamara
et al., 2013), and eEF2 is the target for quinoline-4-carboxamide
(DDD107498) compounds, both with activity against multiple
lifecycle parasite stages (Baraga~na et al., 2015). The eEF2 protein
mediates GTP-dependent translocation of the ribosome along the
mRNA and is required during protein synthesis. The Rab11A protein
is likely involved in cytokinesis and interacts with another anti-
malarial gene-target, the Pfpi4k (McNamara et al., 2013). Only one
non-synonymous SNP was detected for each of these two genes,
supporting their likely essential function. A low number of non-
synonymous SNPs (19.6%) was also detected for the mitochon-
drial cytochrome b (MtcytB) gene. This gene is the target for several
antimalarial compounds under evaluation (Dong et al., 2011) and
atovoquone, a longstanding antimalarial drug used in combination
with proguanil in Malarone™ for the curative and prophylactic
treatment of malaria.
The Pfpi4k gene has the highest percentage of non-synonymousDrug
development
stage
SNP
(non-synonymous)
Non-reference
allele frequency
>5% (non-synonymous)
Known
antimalarial
resistant mutations
Nonclinical
development
44 (28) 5 (3) L550V
Clinical trials 152 (90) 34 (21) 0
Clinical trials 182 (129) 62 (49) 0
Clinical trials 50 (26) 8 (3) 0
Clinical trials 46 (22) 13 (6) 0
Clinical trials 30 (12) 10 (6) 0
Clinical trials 123 (75) 34 (23) 0
Nonclinical
development
66 (31) 16 (9) 0
Clinical trials 5 (1) 0 (0) 0
Preclinical
development
34 (1) 4 (0) 0
Clinical drug,
clinical trial
46 (9) 7 (2) 0
Table 2
Genetic polymorphisms in target-genes at and surrounding resistant linked mutations.
Gene Amino-acid substitutiona Frequency (%) Most frequent Population
PfcPheRs (PF3D7_0109800) M316I 0
T318A 0.47 Bangladesh, Thailand
G512E 0
K519 0.76, 0.96, 2.68 Cambodia, Vietnam, Laos
V545I
V545 2.6, 5.5 DRC, Kenya
L550V 1.79, 0.5 DRC, Ghana
L552 1.1 Guinea
Pfpi4k (PF3D7_0509800) D1311 0.26
S1320L 0
E1355 0.49 Ghana
Y1356F 0
L1479 0.49 Ghana
H1484Y 0
Pfdhodh (PF3D7_0603300) L172F 0
E182D 0
F188L 0
T256 1.052, 0.4 Guinea, Malawi
I263F 0
F227I 0
L515F 0.24, 0.09 Ghana, Thailand
L527I 0
L531F 0
M536I 0.96, 0.19 Laos, Cambodia
Pfcarl (PF3D7_0321900) Q821 0.49 Ghana
P822L 0
L830V 0
E834K 0
S1076N/I 0
D1101G 1.54 Ghana
A1102 0.24 Ghana
V1103L 0
A1135D 0.49 Ghana
L1136P 0
I1139K 0
Pfatp4 (PF3D7_1211900) Q172H 0
V178I
A185S 0.49 Ghana
I203L
V204L
S312P 0
S315 0.02 Malawi
L350H 0
I379N 0
I398F 0
V400A 0
V414D 0
T416N 0
T418N 0
A421L 0
P412L 0
E895K 0
F917L 0
L938I 0
P966A 0
A967G 0
K988R 0.45 Malawi
P990R 0
A1158V
I1205L 0.18, 0.05, 0.5 Gambia, Malawi, Tanzania
A1207V
T1208S 0.11 Guinea
L1242 2.67 DRC
D1247Y 0
Pfcprs (PF3D7_1213800) L482H 0
T1445A 0
C1444T 0
Pfrab11A (PF3D7_1320600) F128 0.96, 0.53 Laos,Vietnam
D139Y 0
PfeEF2 (PF3D7_1451100) E134D 0
Y185N 0
L755F 0
T184I 0
I185T 0
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Table 2 (continued )
Gene Amino-acid substitutiona Frequency (%) Most frequent Population
E336G 0
S473R 0
A481T 0
P756A 0
L757F 0
Pfcytb (Mal_Mito_3) G33A 0
Y126C 0
G131S 0
M133I 0
L144S 0
V150I 0.22 Ghana
V234I 0
V248I 0.1, 12.5 PNG, Nigeria
F267V 0
V284L 0
Pfact (PF3D7_1036800) A94T 0
R108K 0
S110R 0
D165N 0
S169T 0
I190L 2.9, 4.7, 6.7, 3.2, 2.9, 6.7 Bangladesh, Myamar, Thailand,
Vietnam, Cambodia, Laos
C193 0
S242 0
L253 0
G559R 0
pfugt (PF3D7_1113300) F37V 0
a In grey are amino-acid changes or silent mutations linked to drug resistance in vitro.
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dazopyrazines and quinoxaline compounds (McNamara et al.,
2013). This gene probably acts in the Golgi complex and regulates
essential membrane trafﬁcking events (McNamara et al., 2013). We
also detected a high number of non-synonymous SNPs for the
PfcPhers (62.7%), Pfatp4 (60.9%) and Pfcarl (59.2%) genes. The Pfatp4
and Pfcarl have been extensively studied as antimalarial targets.
The Pfcarl is an uncharacterized protein-coding gene that also lo-
calises in the Golgi apparatus of the parasite and the Pfatp4 locus
probably functions as a Naþ-efﬂux ATPase (Flannery et al., 2015;
LaMonte et al., 2016). Several mutations in these genes have pre-
viously been reported, particularly for Pfatp4, to confer resistance to
a growing number of antimalarial compounds that are structurally
unrelated (Table 2). None of these mutations have been identiﬁed
in the set of global ﬁeld isolates considered here. However, several
non-synonymous mutations were observed in their vicinity
(Table 2). The PfcPhers is a recently discovered gene-target that can
be inhibited by a novel compound (bicyclic azetidine BRD3444)
with action in all parasite life stages (liver, blood, and transmission),
andwith the advantage that can act in a single low-dose (Kato et al.,
2016). One of the non-synonymous SNPs identiﬁed for this gene in
the global dataset is a mutation (L550V amino-acid change) linked
to in vitro resistance to BRD3444 (Kato et al., 2016). This mutation
was detected in a few ﬁeld isolates from the Democratic Republic of
Congo (frequency 1.79%) and Ghana (0.5%) (Table 2). We also
detected synonymous SNPs in a codon for which an amino-acid
change (V545I) has also been implicated in resistance to BRD3444.
Although we did not ﬁnd reported antimalarial resistance mu-
tations in any of the other genes in the set of clinical isolates, we
detected some mutations in their vicinity, including several less
than 2 amino-acids away (Table 2). The potential effect of these
natural genetic variants on resistance to antimalarial new compo-
nents should be investigated.
We also assessed the presence of indels and CNVs, as structural
variants have been found to be associated with drug resistance in
antimalarial treatments, including pfmdr1 for meﬂoquine andpfgch1 for sulfadoxine/pyrimethamine (Ravenhall et al., 2016). Copy
number variation in the gene-targets Pfatp4, Pfdhodh, coding for the
enzyme dihydroorotate dehydrogenase (Ross et al., 2014), and
Pfpi4k, have also been identiﬁed in parasite lines resistant to anti-
malarial compounds. No CNVs were identiﬁed across the unique
regions of the eleven candidate genes. Indels in both homo-
polymeric and tandem repetitive regions were detected, none
changing the reading-frame of the respective proteins.
We also investigated if any of the gene-targets was under se-
lective pressure. Tajima's D values were predominantly negative
(82.7%, median0.32 range3.51e1.17) indicating an excess of rare
alleles, consistent with a historical population expansion of
P. falciparum and in keeping with results from genome-wide ana-
lyses (Ravenhall et al., 2016). There was no evidence of positive
directional selection (all jiHSj<2; median ¼ 0.23, min ¼ 1.58,
max ¼ 1.65). There was little evidence of selective pressure in the
candidate regions, implying that they are likely to be evolving
randomly and under neutrality across geographical regions. We
detected several SNPs (63.2%) speciﬁc to a single country (Fig. 1) or
continent (22.7%). Using the 778 SNPs, a principal component
analysis revealed clustering by continent (Fig. 2). The Pfatp4, Pfcarl
and Pfpi4k genes contributed the most to the observed regional
clustering (Supplementary Fig. 1). The FST measure was used to
identify SNPs with allele frequency differences between countries
and continents. This analysis revealed nine SNPs with FST > 0.45,
with clear geographic allelic frequency differences (Supplementary
Table 2), particularly differentiating African from Asian origins.
These SNPs were localized in the Pfatp4, Pfcarl, Pfpi4k and the Pfcprs
genes. The Pfcprs is a cytoplasmic prolyl-tRNA synthetase and a
functional target of febrifugine and its synthetic derivatives with
activity at erythrocytic and liver stages (Herman et al., 2015).4. Discussion
Continuous monitoring of drug efﬁcacy and genome selection
pressure is crucial to ensure early detection and appropriate
Fig. 2. Population structure at a continental level. Principal Components (PC) Analysis plot (x axis represents PC1and y axis PC2) on the ~, 2000 Principal Components (PC)
Analysis plot (x axis represents PC1, and y axis PC2) on the ~2000 P. falciparum ﬁeld samples from 18 countries and using 778 SNPs identiﬁed in the eleven genes-targets.
Fig. 1. Geographic distribution of SNPs across eleven gene-targets. Distribution of genes across countries and continents showed that the majority of SNPs identiﬁed were found
in only one country.
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potential antimalarial gene-targets of compounds that are at
various stages of testing, and for which mutations linked to resis-
tance are known. The availability of whole genome sequencing data
for worldwide ﬁeld isolates enabled us to survey the genetic di-
versity in these targets.We identiﬁed onemutation associated with
in vitro resistance to the antimalarial compounds in low frequency
in two African countries. We also identiﬁed several amino-acid
changes in close proximity to resistance-linked mutations (8 non-
synonymous substitution detected <2 amino-acids away). These
and other mutations detected in these genes might have a role in
the development of resistance, highlighting the need for drug
screening with ﬁeld isolates in addition to laboratory adapted
strains. The high divergence of Plasmodium biology and lack of
crystallized protein structures hindered the assessment of the po-
tential impact of the polymorphisms mutations detected in these
genes.
The genetic diversity described here may have a role upon onset
of selection, and should be taken into account by surveillance
programmes. From these observations, we speculate that for new
antimalarial compounds acting on the PfcPhers gene, acquired
resistance may occur more rapidly in the ﬁeld, as pre-existing
resistant alleles already circulate, although in low frequency, in
clinical isolates. Thus, the identiﬁcation of suitable partner drugs
will be crucial to protect its efﬁcacy. This has been effective in
prolonging the use of some antimalarial drugs (e.g. atovaquone,
artemisinin), which despite resistance readily evolving in vitro and
in the ﬁeld, have been used as effective antimalarials in combina-
tion therapies.
For the Pfrab11A and PfeEF2 gene-targets the particularly low
genetic diversity and detection of only 1 non-synonymous muta-
tion could suggest that new antimalarials targeting these genes
may have a longer lifespan in the ﬁeld. Nevertheless, as antimalarial
resistant mutations have arisen in vitro in all these gene-targets,
and despite several produced low ﬁtness mutants that might not
survive in the human body and not be transmitted, combination
therapies should be considered to increase the useful therapeutic
life of these new compounds.
With the continuous emergence of resistance to artemisinin
derivatives, the introduction of new antimalarial drugs is urgent
and a priori knowledge of the parasite diversity that these drugs are
likely to encounter will aid drug resistance monitoring pro-
grammes. Overall, the genetic information described here for
eleven gene-targets and across 18 countries from malaria endemic
regions, forms a baseline diversity that can assist genetic surveil-
lance studies with detecting allele frequency changes associated
with the pressure imposed by a newly introduced drug.
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